Minhai COVID-19 vaccine

Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.

Minhai COVID-19 vaccine

Vaccine description
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Other names	KCONVAC (Chinese: 可维克; pinyin: Kěwéikè)
Routes of administration	Intramuscular
Legal status
Legal status	Full list of Minhai vaccine authorizations
Identifiers
CAS Number	2698355-03-0

Clinical trials

In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.^[1] Later, KCONVAC started phase II trials with 1,000 participants in China.^[2]

In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.^[3]

Children and adolescents trials

In August 2021, KCONVAC started phase I trials with 84 participants in China.^[4]

In September, KCONVAC started phase II trials with 480 participants in China.^[5]

Authorizations

Full authorization   Emergency authorization   Allowed for travel

See also: List of COVID-19 vaccine authorizations § Minhai

On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.^[6]